On August 27, 2026, the Fifth Circuit affirmed summary judgment for the FDA in both GLP-1 shortage cases, and the cheap-compounded era ended with two unpublished opinions almost nobody in beauty read.
The Outsourcing Facilities Association and FarmaKeio had challenged the agency’s decisions to take semaglutide and tirzepatide off the drug shortage list — the determination that had allowed compounders to produce what were, in practice, copies at scale. The court found the shortage determinations were not arbitrary or capricious, and that even assuming the agency should have run notice-and-comment, the compounders had not shown they were prejudiced by the lack of it. Patient-specific compounding that meets the statutory requirements still exists. The volume business built on the shortage does not.
The citations, since the coverage mostly skipped them. Outsourcing Facilities Association v. Food & Drug Administration, No. 25-10600 (5th Cir. Aug. 27, 2026) is the tirzepatide case. Outsourcing Facilities Association v. Food & Drug Administration, No. 25-10758 (5th Cir. Aug. 27, 2026) is the semaglutide one. Same panel, both on appeal from the Northern District of Texas, and both carrying the line that matters if you are reading them as law: this opinion is not designated for publication. Under Fifth Circuit Rule 47.5 an unpublished opinion is not binding precedent. It binds these parties, it tells you how that court reads the statute, and another court remains free to answer differently. So: a settled commercial reality, and a legal question that is quieter than the headlines made it.
Every piece of coverage I read sorted itself into one of two bins. Clinical and weight-management outlets covered the ruling. Aesthetic outlets went on selling filler for facial volume loss. Nobody put the two in the same paragraph, which is unfortunate, because a very specific reader is standing in the gap.
The reader in the gap
She started a compounded GLP-1 during the shortage, at a price that made sense. Her face changed — the soft, slightly deflated look the internet decided to call Ozempic face, which is mostly just what fat loss looks like above the jaw. She was sold a correction for it: filler, or a biostimulator series, or both, on a maintenance schedule.
Now the supply that made the first decision affordable is gone, and she is holding two recurring bills that were quoted to her separately and were never separate.
Why the aesthetic bill is the harder one
The medication decision has an obvious fork. Brand pricing, a different medication, a legitimate patient-specific prescription if a clinician judges one appropriate, or stopping. Those are real options with real costs and a prescriber to discuss them with.
The face has a quieter problem. Hyaluronic acid filler is an annual operating cost dressed up as a one-time purchase, and a biostimulator is a series before it is a result. Both were priced against a body that was going to stay roughly where it was. If weight changes again in either direction, the volume you paid to replace is not a fixed asset. It is one variable in a face that has several.
Filler placed into a face that later regains soft tissue does not politely step aside. It is still there, doing what it was placed to do, in a face that no longer has the same shape it was correcting.
The question the consultation does not ask
Before the next syringe, the honest question is not whether you like the result. It is whether the underlying condition the result was built on is stable.
Nobody selling facial volume is incentivized to ask that. It is not a sinister omission, mostly — it is that the injector is treating a face in front of them today and has no particular reason to open a conversation about a medication supply chain. But it changes the arithmetic enough that you should open it yourself, in those words, out loud, at the consultation.
- Is my weight likely to be stable over the next twelve to twenty-four months?
- If it is not, what happens to this treatment’s result in either direction?
- What is the two-year cost of this plan as quoted, assuming nothing changes?
- Is there a version of this that waits six months and costs nothing?
The last one is the useful one, and it is the one that never appears on a treatment menu. Waiting is free. It is also the only option in the room whose price does not go up.
Two things I would not chase
I would not chase the supply. The gray market that appears when a legitimate one closes is exactly the market that produced the injectables this publication has spent years writing about, and the pattern is reliable: when a product becomes hard to get at the price people got used to, something appears at that price and it is not the same thing.
And I would not let a volume correction be sold as a fix for something that is still moving. Filler supports a contour. It does not stabilize a face whose underlying tissue is on a trajectory nobody has finished plotting.
Evidence check: Strong (regulatory), Reasoned (aesthetic implication)
Evidence level: the court outcome and its practical effect on compounding are documented, and both opinions are linked below so you can read them rather than take my word for it. Note that both are unpublished and so are not binding precedent. The connection drawn here between medication supply and aesthetic maintenance cost is reasoning from established treatment economics, not a study finding — no trial has measured what happens to filler longevity across weight change.
Sources reviewed September 19, 2026: Outsourcing Facilities Association v. Food & Drug Administration, No. 25-10600 (5th Cir. Aug. 27, 2026) (tirzepatide, USDC N.D. Tex. No. 4:24-CV-953, Eli Lilly and Company intervening) and No. 25-10758 (5th Cir. Aug. 27, 2026) (semaglutide, Novo Nordisk intervening), both affirming summary judgment for FDA, both marked “not designated for publication” and therefore non-precedential under 5th Cir. R. 47.5. FDA statements on compounding policy following stabilization of GLP-1 supply.
The Verdict
The ruling did not change anybody’s face. It changed the price of the thing that was changing it, which is a slower and more expensive problem.
If you are maintaining a facial result that was built during a supply situation which no longer exists, the treatment to pause is the one with the recurring invoice, not the one with the prescription. Give the face six months to tell you where it is actually going. Then buy a correction for that face, rather than for the one that existed at the beginning of a supply chain nobody promised would hold.
This article is general education about cost and treatment planning. Decisions about any prescription medication, including starting, changing or stopping one, belong with your prescriber.
Checked against the Fifth Circuit’s August 27, 2026 decisions in Nos. 25-10600 and 25-10758, both unpublished, and FDA compounding guidance. Reviewed September 19, 2026.
